Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Allergan Inc. pages available for free this week:
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Allergan Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Allergan Inc., profitability ratios (quarterly data)
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
- Gross Profit Margin
- The gross profit margin data, available from March 31, 2010, shows a steadily improving trend over the observed periods. Starting slightly above 82%, it progressively rises each quarter, reaching a peak of 86.6% by December 31, 2014. This indicates an enhancement in the efficiency of production or cost control relative to revenue over time.
- Operating Profit Margin
- The operating profit margin exhibits a significant increase over the analyzed timeframe. Initially low around 5%, it experiences a sharp uplift starting in December 2010, jumping to over 25%, and continues fluctuating within the range of approximately 26% to 30%. This suggests an enhanced operational performance and better management of operating expenses relative to sales, particularly notable from late 2010 onward.
- Net Profit Margin
- Net profit margin shows a pattern similar to the operating margin, with very low or slightly negative values early in 2010 before surging to over 17% by December 2010. Although some fluctuations occur in subsequent quarters, the margin remains relatively strong, generally maintaining levels between 15% and 21%. The elevated net profit margins point toward improved overall profitability after accounting for all expenses and taxes.
- Return on Equity (ROE)
- The return on equity mirrors the net profit margin trend. Starting near zero and occasionally negative in early 2010, it sharply rises in late 2010 to near or above 18%. Although minor oscillations occur, the ROE remains stable around 15% to 20% up to the end of 2014, reflecting consistent returns generated on shareholders' equity.
- Return on Assets (ROA)
- Return on assets follows a similar trajectory as ROE but at a somewhat lower level, as expected. Starting near zero and slightly negative at the beginning of 2010, it increases substantially by late 2010 to over 11%. Throughout the following periods, ROA stabilizes mostly between 9% and 12%, indicating effective utilization of the company's assets in generating earnings over the reported quarters.
Return on Sales
Return on Investment
Gross Profit Margin
Allergan Inc., gross profit margin calculation (quarterly data)
| Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Gross profit | ||||||||||||||||||||||||||
| Product net sales | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Gross profit margin1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
1 Q4 2014 Calculation
Gross profit margin = 100
× (Gross profitQ4 2014
+ Gross profitQ3 2014
+ Gross profitQ2 2014
+ Gross profitQ1 2014)
÷ (Product net salesQ4 2014
+ Product net salesQ3 2014
+ Product net salesQ2 2014
+ Product net salesQ1 2014)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data shows several notable trends in the quarterly performance over the analyzed period. Both gross profit and product net sales exhibit a consistent upward trajectory, reflecting growth in the company's revenue-generating activities and profitability.
- Gross Profit
- Gross profit steadily increased from approximately $898.5 million in the first quarter of 2010 to about $1.65 billion by the end of 2014. This progression indicates sustained improvement in the company’s earnings after accounting for the cost of goods sold, with only minor fluctuations. Notable increments occur towards the end of each year, suggesting possible seasonal influences or effective cost management strategies.
- Product Net Sales
- Product net sales parallel the growth pattern of gross profit, rising from roughly $1.11 billion in early 2010 to nearly $1.89 billion by late 2014. This steady increase demonstrates enhanced market demand or pricing power over the period. There is a consistent quarter-over-quarter improvement, with strong performances frequently observed in the third and fourth quarters, which may reflect marketing campaigns or product launches.
- Gross Profit Margin
- The gross profit margin shows a gradual but consistent increase from 82.16% in March 2011 to 86.6% at the end of 2014. This improvement suggests enhanced operational efficiency and possibly better pricing strategies or cost structures. The margins have improved by over 4 percentage points during the period, underscoring the company’s growing ability to convert sales into profit.
Overall, the data indicates a positive financial trend with increasing revenues, improving profitability, and enhanced margins. The steady margin expansion alongside revenue growth suggests effective cost control and value creation, positioning the company favorably in its market segment throughout the analyzed span.
Operating Profit Margin
Allergan Inc., operating profit margin calculation (quarterly data)
| Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Operating income (loss) | ||||||||||||||||||||||||||
| Product net sales | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Operating profit margin1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
1 Q4 2014 Calculation
Operating profit margin = 100
× (Operating income (loss)Q4 2014
+ Operating income (loss)Q3 2014
+ Operating income (loss)Q2 2014
+ Operating income (loss)Q1 2014)
÷ (Product net salesQ4 2014
+ Product net salesQ3 2014
+ Product net salesQ2 2014
+ Product net salesQ1 2014)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial performance over the analyzed periods exhibits notable fluctuations and gradual growth tendencies in key metrics. Operating income displayed significant volatility, particularly marked by a substantial loss in the third quarter of 2010, followed by a recovery and steady positive performance thereafter. From the first quarter of 2011 onward, operating income remained consistently positive, with noticeable increases that peaked towards the end of 2014, indicating improved operational efficiency or favorable market conditions.
Product net sales demonstrated a general upward trend throughout the observed quarters. Starting from just above 1.1 billion US dollars in early 2010, sales consistently increased, reaching nearly 1.9 billion by the end of 2014. This steady growth suggests successful sales strategies and potentially expanding market demand for the company's products over the period.
The operating profit margin, available from the first quarter of 2011 forward, remained relatively stable with slight upward movements. Initially, margins hovered around 5%, but from late 2011 onwards, they increased significantly, maintaining levels generally between 25% and 30%. The consistent margin in this range towards the end of the period reflects sustained profitability and efficient cost management relative to sales revenue.
- Operating Income (US$ in thousands)
- Experienced a pronounced loss in Q3 2010, with rapid recovery in subsequent quarters. Consistent positive income was recorded from early 2011 onwards, peaking near the end of 2014, indicating stabilization and growth in earnings.
- Product Net Sales (US$ in thousands)
- Displayed a steady increase across all quarters, rising from approximately 1.1 billion in early 2010 to nearly 1.9 billion by the end of 2014, reflecting a strong sales growth trajectory.
- Operating Profit Margin (%)
- Margins improved from around 5% in early 2011 to a stable range between 25% and 30% from late 2011 through 2014, demonstrating enhanced profitability and operational efficiency over time.
Net Profit Margin
Allergan Inc., net profit margin calculation (quarterly data)
| Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net earnings (loss) attributable to Allergan, Inc. | ||||||||||||||||||||||||||
| Product net sales | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| Net profit margin1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
1 Q4 2014 Calculation
Net profit margin = 100
× (Net earnings (loss) attributable to Allergan, Inc.Q4 2014
+ Net earnings (loss) attributable to Allergan, Inc.Q3 2014
+ Net earnings (loss) attributable to Allergan, Inc.Q2 2014
+ Net earnings (loss) attributable to Allergan, Inc.Q1 2014)
÷ (Product net salesQ4 2014
+ Product net salesQ3 2014
+ Product net salesQ2 2014
+ Product net salesQ1 2014)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The financial data reveals several notable trends in the company's quarterly performance over the analyzed periods. Net earnings attributable to the company exhibit considerable volatility in the earlier years, including a significant loss reported in the third quarter of 2010. Following this period, net earnings show a general upward trajectory, with occasional fluctuations, culminating in substantially higher earnings in the later quarters, particularly by the end of 2014.
Product net sales demonstrate consistent growth throughout the entire period. Starting from just over one billion US dollars in the first quarter of 2010, product sales increase steadily each quarter, reaching nearly two billion US dollars by the final reported quarter. This upward trend indicates expanding revenues from the company's core product offerings.
Net profit margins, available from the first quarter of 2011 onwards, reflect initial instability with negative values indicating losses in the early quarters of 2011. From the fourth quarter of 2011, profit margins stabilize and improve substantially, remaining in the high teens percentage range and reaching over 21% by the last quarter of 2014. This improvement in profit margins aligns with the growth observed in net earnings and product sales, signifying enhanced operational efficiency or favorable cost management relative to revenues.
- Net Earnings
- Exhibited significant volatility early on, including a large loss in Q3 2010. Recovery and growth followed, with earnings generally trending upwards and peaking in Q4 2014.
- Product Net Sales
- Displayed consistent and steady growth throughout the periods, nearly doubling from approximately $1.1 billion in Q1 2010 to nearly $1.9 billion in Q4 2014, indicating strong market performance.
- Net Profit Margin
- Initially unstable with negative margins in early 2011, margins improved markedly from Q4 2011 onward, maintaining a robust range of about 15-21%. The margin growth corresponds with increased earnings and sales.
Overall, the data suggests a company recovering from early financial difficulties, achieving sustained revenue growth, improving profitability, and enhancing its financial performance as demonstrated by both rising net earnings and expanding profit margins.
Return on Equity (ROE)
Allergan Inc., ROE calculation (quarterly data)
| Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net earnings (loss) attributable to Allergan, Inc. | ||||||||||||||||||||||||||
| Total Allergan, Inc. stockholders’ equity | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROE1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROE, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
1 Q4 2014 Calculation
ROE = 100
× (Net earnings (loss) attributable to Allergan, Inc.Q4 2014
+ Net earnings (loss) attributable to Allergan, Inc.Q3 2014
+ Net earnings (loss) attributable to Allergan, Inc.Q2 2014
+ Net earnings (loss) attributable to Allergan, Inc.Q1 2014)
÷ Total Allergan, Inc. stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Earnings (Loss) Attributable to Allergan, Inc.
- The net earnings exhibit considerable volatility across the quarters. Beginning in March 2010, net earnings were positive at 167.9 million USD and increased to 240.1 million USD by June 2010. However, the company reported a significant loss of 670.5 million USD in September 2010, the most notable negative figure in the series. Following this period, the net earnings recovered steadily through the remainder of 2010 and into 2011, ending 2011 at 279.8 million USD. From 2012 onward, net earnings generally showed an upward trend with some fluctuations. For example, the first quarter of 2013 exhibited a marked decrease to 12.5 million USD, a sharp drop from the previous quarter. This was followed by increases through the remainder of 2013 and into 2014, with the highest net earnings recorded in December 2014 at 537.2 million USD.
- Total Allergan, Inc. Stockholders’ Equity
- Stockholders’ equity demonstrated a consistent upward trajectory over the entire period observed. Starting at approximately 4.94 billion USD in March 2010, the equity base increased gradually each quarter. There was a slight dip in September 2010 correlating with the significant net loss observed in the same quarter, but the overall trend continued upwards thereafter. By the end of 2014, total stockholders’ equity had increased substantially to 7.75 billion USD, indicating sustained growth in the company's net assets.
- Return on Equity (ROE)
- The ROE data is only available starting from March 2011. Initially, the return on equity was near zero or slightly negative, with values of 0.01% in March 2011 and negative values in the following two quarters, reflecting the earlier volatility in earnings. From December 2011 onwards, ROE sharply improved and stabilized around a high range from approximately 16.5% to 19.7% across the subsequent quarters. This indicates an enhanced ability of the company to generate earnings from its equity base during this time frame.
- Overall Analysis
- The financial data indicates a period of instability around late 2010 with significant losses but a recovery phase commencing in late 2010 and solidifying through 2011. The consistent increase in stockholders’ equity combined with steadily improving and high ROE from late 2011 onward reflects improved profitability and capital efficiency. Despite short-term earnings fluctuations, especially the anomalously low earnings in early 2013, the company showed strong financial growth and profitability by the end of 2014.
Return on Assets (ROA)
Allergan Inc., ROA calculation (quarterly data)
| Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 | Mar 31, 2014 | Dec 31, 2013 | Sep 30, 2013 | Jun 30, 2013 | Mar 31, 2013 | Dec 31, 2012 | Sep 30, 2012 | Jun 30, 2012 | Mar 31, 2012 | Dec 31, 2011 | Sep 30, 2011 | Jun 30, 2011 | Mar 31, 2011 | Dec 31, 2010 | Sep 30, 2010 | Jun 30, 2010 | Mar 31, 2010 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | ||||||||||||||||||||||||||
| Net earnings (loss) attributable to Allergan, Inc. | ||||||||||||||||||||||||||
| Total assets | ||||||||||||||||||||||||||
| Profitability Ratio | ||||||||||||||||||||||||||
| ROA1 | ||||||||||||||||||||||||||
| Benchmarks | ||||||||||||||||||||||||||
| ROA, Competitors2 | ||||||||||||||||||||||||||
| AbbVie Inc. | ||||||||||||||||||||||||||
| Amgen Inc. | ||||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | ||||||||||||||||||||||||||
| Danaher Corp. | ||||||||||||||||||||||||||
| Eli Lilly & Co. | ||||||||||||||||||||||||||
| Gilead Sciences Inc. | ||||||||||||||||||||||||||
| Johnson & Johnson | ||||||||||||||||||||||||||
| Merck & Co. Inc. | ||||||||||||||||||||||||||
| Pfizer Inc. | ||||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | ||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | ||||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | ||||||||||||||||||||||||||
Based on: 10-K (reporting date: 2014-12-31), 10-Q (reporting date: 2014-09-30), 10-Q (reporting date: 2014-06-30), 10-Q (reporting date: 2014-03-31), 10-K (reporting date: 2013-12-31), 10-Q (reporting date: 2013-09-30), 10-Q (reporting date: 2013-06-30), 10-Q (reporting date: 2013-03-31), 10-K (reporting date: 2012-12-31), 10-Q (reporting date: 2012-09-30), 10-Q (reporting date: 2012-06-30), 10-Q (reporting date: 2012-03-31), 10-K (reporting date: 2011-12-31), 10-Q (reporting date: 2011-09-30), 10-Q (reporting date: 2011-06-30), 10-Q (reporting date: 2011-03-31), 10-K (reporting date: 2010-12-31), 10-Q (reporting date: 2010-09-30), 10-Q (reporting date: 2010-06-30), 10-Q (reporting date: 2010-03-31).
1 Q4 2014 Calculation
ROA = 100
× (Net earnings (loss) attributable to Allergan, Inc.Q4 2014
+ Net earnings (loss) attributable to Allergan, Inc.Q3 2014
+ Net earnings (loss) attributable to Allergan, Inc.Q2 2014
+ Net earnings (loss) attributable to Allergan, Inc.Q1 2014)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The quarterly financial data reveals several key trends over the observed periods. Net earnings attributable to the company exhibited significant volatility initially, with a notable large loss recorded in the third quarter of 2010. This was followed by a general recovery and stabilization in earnings from late 2010 onward, with a predominant upward trend observed through to the end of 2014. Earnings peaked multiple times, notably in the final quarter of 2014, indicating a return to strong profitability.
Total assets demonstrated a consistent and steady increase throughout the entire duration. Starting from approximately 7.6 billion US dollars in early 2010, assets grew steadily each quarter, reaching over 12.4 billion US dollars by the last quarter of 2014. This sustained growth in asset base suggests ongoing investments or acquisitions, contributing to expanding operational capacity or value.
Return on Assets (ROA) data, though incomplete in the earlier periods, provides insight from the first quarter of 2011 onward. Initial values showed some negative returns but quickly shifted to positive territory with considerable improvement. ROA stabilized around double-digit percentages for subsequent quarters, generally fluctuating between 9% and 12%, culminating in a peak of around 12.3% at the end of 2014. This indicates efficient asset utilization contributing to profitability during the later periods.
- Net Earnings (Loss)
- Highly volatile in early 2010 with a significant loss in Q3, followed by recovery and consistent positive earnings from late 2010 through 2014.
- Strong upward trajectory in earnings, peaking at over 530 million USD in Q4 2014.
- Total Assets
- Continuous growth from 7.6 billion USD in Q1 2010 to over 12.4 billion USD by Q4 2014.
- Indicates ongoing asset accumulation and possible expansion activities.
- Return on Assets (ROA)
- Initial negative values in early 2011 corrected to consistently positive returns thereafter.
- Stable performance in the range of approximately 9% to 12%, suggesting effective asset utilization.
- Highest ROA observed at the end of 2014, supporting the trend of improved profitability.